Memorial Sloan Kettering Cancer Center
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Memorial Sloan Kettering Cancer Center sits in the top decile of US sponsors by registered trial count (#6 of 15,751 sponsors by registered trial count).
Memorial Sloan Kettering Cancer Center: 1,884 sponsored US clinical trials, 327 recruiting.
Memorial Sloan Kettering Cancer Center sponsors 1,884 registered US clinical trials on ClinicalTrials.gov, 327 of them currently recruiting, and 1,104 completed. 75 of these trials are in Phase 3-4 (later-stage) and 1,101 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Breast Cancer, with 98 trials.
Top-decile sponsor footprint
Memorial Sloan Kettering Cancer Center ranks in the top decile of sponsors by registered trial count (#6 of 15,751 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Open and recent trials
1,884 total, page 33 of 38
Intensive Chemotherapy and Autotransplantation for Patients With Newly Diagnosed Anaplastic Oligodendroglioma
NCT00588523
Docetaxel in Treating Older Patients With Metastatic Breast, Lung, or Prostate Cancer
NCT00059943
High-Dose Radiation Therapy Plus Chemotherapy in Treating Patients With Advanced Nose or Throat Cancer
NCT00052429
Combined Immunochemotherapy Followed By Reduced Dose Radiation Therapy (RT) for Patients With Newly Diagnosed Primary Central Nervous System Lymphoma
NCT00594815
Erlotinib and Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer
NCT00049101
Effect of Soy Supplementation on Cellular Markers in Normal and Cancerous Breast Tissue: A Randomized Placebo Controlled Study
NCT00597532
Imatinib Mesylate and Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer
NCT00045604
UCN-01 and Fluorouracil in Treating Patients With Metastatic Pancreatic Cancer
NCT00045747
BMS-247550 and Gemcitabine in Treating Patients With Advanced Solid Tumors
NCT00043095
Vaccination of AJCC Stage IIB, IIC, III and IV Melanoma Patients With Human and Mouse Tyrosinase DNA Vaccines
NCT00698100
Longitudinal Assessment of Health-Related Quality of Life in Men With Localized Prostate Cancer
NCT00582842
Propofol's Hypnotic and Memory Effects
NCT00576615
Melphalan, Thalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed, Previously Untreated Primary Systemic Amyloidosis
NCT00089167
FR901228 in Treating Patients With Myelodysplastic Syndrome, Acute Myeloid Leukemia, or Non-Hodgkin's Lymphoma
NCT00042822
Interferon Alfa and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia
NCT00045422
Beclomethasone Plus Prednisone in Treating Patients With Graft-Versus-Host Disease
NCT00043147
PEG-Interferon Alfa-2b in Treating Patients With Metastatic Kidney Cancer
NCT00045279
Chemotherapy and Biological Therapy in Treating Patients With Locally Advanced or Metastatic Kidney Cancer
NCT00045370
Pyroxamide in Treating Patients With Advanced Cancer
NCT00042900
Combination Chemotherapy in Treating Patients With Advanced Solid Tumors
NCT00045448
Vaccine Therapy Plus QS21 in Treating Patients With Prostate Cancer
NCT00036933
Ph II OSI-774 (Erlotinib,Tarceva) In Advanced Bronchioloalveolar Cell Lung Cancer
NCT00590902
Acupuncture and Acupressure in Treating Patients With Moderate or Severe Pain Related to Stage III or Stage IV Pancreatic Cancer
NCT00040833
TLK286 in Treating Patients With Advanced Non-Small Cell Lung Cancer
NCT00036920
Immunotoxin Therapy Before and After Surgery in Treating Patients With Recurrent Malignant Glioma
NCT00036972
Beta-Glucan and Monoclonal Antibody in Treating Patients With Metastatic Neuroblastoma
NCT00037011
Bortezomib and Carboplatin in Treating Patients With Recurrent or Progressive Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer
NCT00028912
Molecular Genetic Basis of Invasive Breast Cancer Risk Associated With Lobular Carcinoma in Situ
NCT00581750
Bortezomib in Treating Patients With Advanced or Metastatic Sarcoma
NCT00027716
Bexarotene and Interferon Alfa in Treating Patients With Cutaneous T-Cell Lymphoma
NCT00030849
Positron Emission Tomography Before Surgery in Evaluating Women With Primary or Recurrent Breast Cancer
NCT00039286
Combination Chemotherapy in Treating Patients With Locally Advanced or Metastatic Cancer of the Esophagus
NCT00030862
Tumor Detection Using Iodine-131-Labeled Monoclonal Antibody 8H9
NCT00582608
Immune Responses To Antigen-Bearing Dendritic Cells in Patients With Malignancy
NCT00700167
Measurement of Cancer-Related Risk Perception in Smokers
NCT00588211
Total-Body Irradiation and Chemotherapy Followed By Donor Bone Marrow Transplant in Treating Young Patients With Hematologic Cancer
NCT00028730
Adjuvant Docetaxel Plus Gemcitabine in Patients With Completely Resected Leiomyosarcoma (LMS) of the Uterus
NCT00614835
Portal Vein Embolization in Treating Patients With Liver Metastases From Primary Colorectal Cancer
NCT00028626
Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Cancer
NCT00045006
Temozolomide and Vinorelbine in Treating Patients With Recurrent Brain Metastases
NCT00026494
Ixabepilone With or Without Estramustine in Treating Patients With Progressive Prostate Cancer
NCT00025194
Rapid Hormonal Cycling as Treatment for Patients With Prostate Cancer: The Men's Cycle
NCT00586898
Melphalan, Fludarabine, and Alemtuzumab Followed by Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer
NCT00027560
A Multicenter Trial On The Utility and Impact Of Computed Tomography and Serum CA-125 In the Management of Newly Diagnosed Ovarian Cancer
NCT00587093
Hematopoietic Stem Cell Transplantation for Treatment of Patients With Fanconi Anemia Lacking a Genotypically Identical Donor, Using Total Body Irradiation, Cyclophosphamide and Fludarabine
NCT00595127
Monoclonal Antibody Therapy in Treating Patients With Prostate Cancer
NCT00024232
Trial of Allogeneic Stem Cell Transplants From HLA Compatible, Related and Unrelated Donors After a Myeloablative Preparative Regimen With Hyperfractionated TBI, Thiotepa and Fludarabine For Adult Patients With Lymphohematopoietic Disorders
NCT00587054
Monoclonal Antibody Therapy in Treating Patients With Advanced Colorectal Cancer
NCT00027729
Phase II Trial of a Chemotherapy Alone Regimen of IV Busulfan (Busulfex), Melphalan and Fludarabine as Myeloablative Regimen Followed by an Allogeneic T-Cell Depleted Hematopoietic Stem Cell Transplant From an HLA-Identical, or HLA-Non Identical Related or Unrelated Donor
NCT00582933
10-Propargyl-10-Deazaaminopterin Plus Probenecid in Treating Patients With Advanced Solid Tumors
NCT00024245
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 461 |
| Phase 2 | 640 |
| Phase 3 | 67 |
| Phase 4 | 8 |
Therapeutic Areas
What is open in the Memorial Sloan Kettering Cancer Center pipeline
327 recruiting of 1,884 indexed (17% open); 1,104 completed (59%).
Phase mix: 75 late (III/IV) vs 1,101 early (I/II) (early-phase heavy).
Top condition: Breast Cancer (98 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial from this sponsor, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.